Lenvatinib Exhibits Potent Anti-tumor Activity and Favorable Safety Profile in a Colorectal Cancer Xenograft Model
Chen-Yu Kuo1, Tsai-Lan Liao2, Fei-Ting Hsu3
1Division of Gastroenterology, Department of Medicine, National Yang Ming Chiao Tung University Hospital, Yilan, Taiwan, R.O.C.
Background/Aim:
Lenvatinib, a multikinase inhibitor, has shown potential anti-tumor activity in various cancers. This study evaluated its efficacy, safety, and apoptotic mechanisms in colorectal cancer (CRC) using HT-29 xenograft-bearing mice.
Materials And Methods:
Mice were treated with lenvatinib at 0, 10, or 20 mg/kg for 20 days. Tumor growth, serum biochemistry, and histopathology were assessed. Protein expression related to ERK signaling and apoptosis was analyzed using immunohistochemistry.
Results:
Lenvatinib significantly suppressed CRC tumor growth, delaying progression up to 14-fold compared with controls. No body-weight loss or hepatic/renal toxicity was observed, indicating good tolerability. Mechanistically, lenvatinib reduced phosphorylated ERK and anti-apoptotic proteins (BCL-2, c-FLIP, XIAP) by 30-50%, while enhancing cleaved caspase-3, -8, -9, BAX, and BAK expression by 1.2-1.5-fold, promoting apoptosis.
Conclusion:
Lenvatinib exhibits potent anti-CRC activity with minimal systemic toxicity. Its therapeutic effects are mediated through ERK pathway inactivation, suppression of anti-apoptotic proteins, and induction of caspase-dependent apoptosis.
Insights
Lenvatinib effectively inhibits colorectal cancer (CRC) growth in mice by inducing apoptosis and inactivating the ERK pathway, demonstrating significant anti-tumor activity with minimal toxicity.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Lenvatinib is a multikinase inhibitor with demonstrated anti-tumor effects in various cancers.
- Colorectal cancer (CRC) remains a significant global health challenge, necessitating novel therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy and safety of lenvatinib in a colorectal cancer (CRC) mouse model.
- To elucidate the apoptotic mechanisms underlying lenvatinib's anti-tumor activity in CRC.
Main Methods:
- HT-29 colorectal cancer xenografts were established in mice and treated with lenvatinib (0, 10, or 20 mg/kg) for 20 days.
- Tumor growth, serum biochemistry, and histopathology were analyzed.
- Protein expression related to ERK signaling and apoptosis was assessed via immunohistochemistry.
Main Results:
- Lenvatinib significantly suppressed CRC tumor growth, delaying progression up to 14-fold compared to controls.
- No significant body weight loss or hepatic/renal toxicity was observed, indicating good tolerability.
- Lenvatinib reduced phosphorylated ERK and anti-apoptotic proteins (BCL-2, c-FLIP, XIAP) by 30-50% and increased pro-apoptotic proteins (cleaved caspase-3, -8, -9, BAX, BAK) by 1.2-1.5 fold.
Conclusions:
- Lenvatinib demonstrates potent anti-CRC activity with a favorable safety profile.
- Therapeutic effects are attributed to ERK pathway inactivation, reduced anti-apoptotic protein levels, and enhanced caspase-dependent apoptosis.
More Related Videos
09:28Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
10:33Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts
Published on: April 29, 2014
Related Concept Videos
Gibbs Free Energy and Thermodynamic Favorability
Survey Safety
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Household Wiring And Electrical Safety
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
